Research and Clinical Trials

A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma
Brief Description  
This trial is studying how well gemcitabine and erlotinib work when given before and after surgery in treating patients with pancreatic cancer that can be removed by surgery.
Who may be Eligible  
Inclusion Criteria:
  1. Cytologic or histologic proof of adenocarcinoma of the pancreatic head or uncinate process
  2. only.
  3. Localized, potentially resectable tumors.
  4. >1= 18 years of age
  5. ECOG/Zubrod PS 0 or I
  6. Baseline weight loss
  7. CA19-9<1,000
Exclusion Criteria:
  1. No history of prior EGFR targeted therapy or therapy for pancreatic cancer
  2. No active infection requiring IV antibiotics at time of registration
  3. No prior malignancy within 5 years of registration
Gastrointestinal Cancer
IRB Number  
Principal Investigator  
Martinie, John

For More Information, Contact  Tesa  , Adams
Phone:  (704) 446-5145  Fax:  (704) 355-1353  
Address:1100 South Tryon Street Suite 220